Arbutus Biopharma/$ABUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arbutus Biopharma
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Ticker
$ABUS
Sector
Primary listing
Employees
19
Headquarters
Website
ABUS Metrics
BasicAdvanced
$853m
5.17
$0.84
0.62
-
Price and volume
Market cap
$853m
Beta
0.62
52-week high
$5.10
52-week low
$3.04
Average daily volume
1.4m
Financial strength
Current ratio
54.263
Quick ratio
54.002
Long term debt to equity
1.26
Total debt to equity
1.502
Interest coverage (TTM)
1,803.41%
Profitability
EBITDA (TTM)
155.137
Gross margin (TTM)
89.34%
Net profit margin (TTM)
83.95%
Operating margin (TTM)
81.01%
Revenue per employee (TTM)
$10,080,000
Management effectiveness
Return on assets (TTM)
49.18%
Return on equity (TTM)
94.73%
Valuation
Price to earnings (TTM)
5.171
Price to revenue (TTM)
4.341
Price to book
3.27
Price to tangible book (TTM)
3.27
Price to free cash flow (TTM)
-24.189
Free cash flow yield (TTM)
-4.13%
Free cash flow per share (TTM)
-0.179
Growth
Revenue change (TTM)
2,889.93%
Earnings per share change (TTM)
-305.92%
3-year revenue growth (CAGR)
79.46%
10-year revenue growth (CAGR)
24.86%
3-year earnings per share growth (CAGR)
22.54%
10-year earnings per share growth (CAGR)
-4.18%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs